Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 and HX008 in EGFR-positive Advanced Solid Tumors
NCT05688605Phase 2Recruiting
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in solid tumor, sponsored by Lepu Biopharma Co., Ltd.. Started Jun 2022; status: recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05688605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688605.